Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Interferon alfacon

Interferon alfacon-1 (Inferax ), interferon alfa-2b (IntronA ), and interferon alfa-2a (Roferon -A) are applied in the treatment of chronic hepatitis B and C and some malignancies, especially hairy cell leukemia. IFN-a proteins induce the expression of antiviral, antiproliferative and immunomodulatory genes. [Pg.411]

Interferon alfa-2a (Roferon A), interferon alfa-2b (Intron-A), and interferon alfacon-1 (Infergen) are approved for chronic hepatitis C. However, they are not prescribed alone because only 12% to 16% of patients achieve a sustained virologic response (SVR). Adding ribavirin, a synthetic guanosine analogue that inhibits viral polymerase, increases the SVR rate to 35% to 45%. [Pg.356]

Infergen (interferon alfacon-1 or consensus interferon) is an engineered interferon recently approved for the treatment of hepatitis C (Table 8.8). The development of infergen entailed initial sequence comparisons between a range of IFN-as. The product s amino acid sequence reflects the most frequently occurring amino acid residue in each corresponding position of these native interferons. A DNA sequence coding for the product was synthesized and inserted into E. coli. The recombinant product accumulates intracellularly as inclusion bodies. [Pg.228]

Alberti, A. 1999. Interferon alfacon-1. A novel interferon for the treatment of chronic hepatitis C. Biodrugs 12(5), 343-357. [Pg.238]

Interferon Alfacon-1 - 30% identity with IFN-P Chronic hepatitis C... [Pg.60]

Pharmacokinetics The pharmacokinetic properties of Infergen have not been evaluated in patients with chronic hepatitis C. Pharmacokinetic profiles were evaluated in normal, healthy volunteer subjects after subcutaneous injection of interferon alfacon-1 at doses up to 9 j,g. Plasma levels of interferon alfacon-1 at any dose were too low to be detected. However, analysis of Infergen-induced cellular products— induction of 2 5 oligoadenylate synthetase and (beta)-2 microglobulin—after treatment in these subjects revealed a statistically significant, dose-related increase in the area under the curve (AUC). [Pg.189]

F. Role in therapy Interferon alfacon-1 is an option for the initial treatment of patients with HCV infection and for subsequent treatment in patients who did not respond or relapsed after initial interferon therapy. For initial treatment, however, other therapies are usually more effective. [Pg.190]

Recommended dosage and monitoring requirements The recommended dose of Roferon-A for chronic hepatitis C is 3 million international units (MIU) three times a week for 12 months. The recommended dose for CML is 9 MIU daily optimal duration of therapy has not been determined. The recommended dose for hairy cell leukemia is 3 MIU daily for 16 to 24 weeks. The recommended dose for AIDS-related Kaposi s sarcoma is 36 MIU daily for 10 to 12 weeks. There are five types of interferon alfa currently available in the United States interferon alfa-2a, peginterferon alfa-2a, interferon alfa-2b, interferon alfacon-1, and interferon alfa n3. Doses are not consistent for these preparations. [Pg.190]

Interferons and cytokines Interferon alfacon-1, human recombinant, produced in E. coli Infergen Sterile solution, SDV and prefilled syringes containing 9 j,g in 0.3 ml or 15 j,g in 0.5 ml SC... [Pg.461]

Interferon alfacon-1, human recombinant, produced in E. coli. [Pg.515]

Interferon alfacon-1 Chronic hepatitis C 9-15 meg three times weekly as monotherapy Subcutaneous... [Pg.1084]

Parenteral 5 million IU/vial Interferon alfacon-1 (Infergen)... [Pg.1089]

INFERGEN (interferon alfacon-1) [E. coli-expressed recombinant protein]... [Pg.318]

Interferon alfacon-1 Chronic hepatitis C2 9 ug three times weekly (consider 15 g three times weekly if patient relapses or is unresponsive) Subcutaneous... [Pg.1146]

Interferon alfa-2a and interferon alfa-2b may be administered subcutaneously or intramuscularly, while interferon alfacon-1 is administered subcutaneously (see Table 49-5). Maximum serum... [Pg.1148]

Infergen Interferon alfacon-l Amgen 10/1997 Chronic hepatitis C virus (HCV) infection E. coli... [Pg.1423]

Interferons interferon alpha-nl, interferon alpha-n3, interferon alpha-2a, peg interferon alfa-2b, interferon alfacon-1, Interferon alpha-2b, interferon beta-lb, interferon gamma-lb,... [Pg.36]

A 47-year-old man, who had previously received a 2-month course of interferon alfacon-1 for chronic hepatitis C, started interferon alfa-2b 8 months later (320). He developed mild generalized pruritus the day after the second injection, and dyspnea with diffuse urticaria within a few hours after the third injection. Skin tests were not performed, and IgG but not IgE antibodies to interferon alfa were found. [Pg.1812]

Interferon alfacon-l is u.sed in the treatment of chronic hepatitis C virus infection in patients 18 years of age or older with compensated liver disease and who have anti-HCV scrum antibodies or HCV RNA. [Pg.181]

The drug is administered by the subcutaneous route in a dose of 9 g 3 times per week. Interferon alfacon-l is supplied us a solution in phosphate-buffered saline. It should be stored at 2 to 8°C without freezing. Avoid shaking the solution. [Pg.181]

Melian EB, Plosker GL. Interferon alfacon-1 A review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 2001 61 1661-1691. [Pg.759]

INFERGEN (interferon alfacon-1) E. coli-expressed recombinant protein] (InterMune) CFP Farma-ceutica (European Union) Amgen (U.S.) Liquid 9 pg singledose vials or 15 pg single-dose vials 9 pg in 0.3 mL 15 pg in 0.5 mL (pH 7.0 0.2) Per vial 5.9 mg/mL sodium chloride 3.8 mg/mL sodium phosphate... [Pg.318]

USA interferon alfacon-1 interferon Infergen Advaferon, Inferax Recombinant consensus human lymphoblast interferon alpha expressed in E. coli Antiviral... [Pg.471]

Interferon alfacon-I is an immnnomodnlator. These small protein molecules bind to specific cell-snrface receptors and initiate complex sequences of intracellnlar events, including production of enzymes and other prodnets with antiviral, antiproliferative, and immunomodnlatory effects. They are indicated in the treatment of chronic hepatitis C virus (HVC) infection in patients older than 18 years of age with compensated liver disease who have anti-HCV sernm antibodies and/or the presence of HCV RNA. [Pg.356]

See other pages where Interferon alfacon is mentioned: [Pg.590]    [Pg.614]    [Pg.592]    [Pg.616]    [Pg.579]    [Pg.635]    [Pg.188]    [Pg.188]    [Pg.188]    [Pg.188]    [Pg.488]    [Pg.515]    [Pg.515]    [Pg.556]    [Pg.1084]    [Pg.1148]    [Pg.1149]    [Pg.944]    [Pg.96]    [Pg.181]    [Pg.331]    [Pg.356]   
See also in sourсe #XX -- [ Pg.635 ]

See also in sourсe #XX -- [ Pg.188 , Pg.189 ]

See also in sourсe #XX -- [ Pg.356 ]

See also in sourсe #XX -- [ Pg.138 ]

See also in sourсe #XX -- [ Pg.108 ]



SEARCH



Antivirals interferon alfacon

© 2024 chempedia.info